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Pelationship Between Increasing Body
eight, Insulin Resistance, Inflammation,
dipocytokine Leptin, and Coronary Circulatory Function
homas H. Schindler, MD,* Jerson Cardenas, MD,* John O. Prior, MD, PHD,* Alvaro D. Facta, MD,*
ichael C. Kreissl, MD,* Xiao-Li Zhang, MD, PHD,* James Sayre, PHD,* Magnus Dahlbom, PHD,*
ulio Licinio, MD,† Heinrich R. Schelbert, MD, PHD*
os Angeles, California
OBJECTIVES We sought to evaluate effects of obesity, insulin resistance, and inflammation on coronary
circulatory function and its relationship to leptin plasma levels.
BACKGROUND It is not known whether obesity, commonly paralleled by insulin resistance, inflammation,
and leptin, is independently associated with coronary circulatory dysfunction.
METHODS Myocardial blood flow (MBF) responses to cold pressor test (CPT) and pharmacologic
vasodilation was measured with positron emission tomography and 13N-ammonia. Study
participants were divided into three groups based on their body mass index (BMI, kg/m2):
control, 20  BMI 25 (n  19); overweight, 25  BMI 30 (n  21); and obese, BMI
30 (n  32).
RESULTS Body mass index was significantly correlated to the Homeostasis Model Assessment Index of
insulin resistance and C-reactive protein levels (r  0.60 and r  0.47, p  0.0001).
Compared with control subjects, endothelium-related change in MBF (MBF) to CPT
progressively declined in overweight and obese groups (0.32  0.09 vs. 0.21  0.19 and
0.07  0.16 ml/g/min; p  0.03 and p  0.0001). The dipyridamole-induced total
vasodilator capacity was significantly lower in obese than in control subjects (1.77  0.51 vs.
2.04  0.37 ml/g/min, p  0.02). On multivariate analysis, BMI (p  0.012) and age (p 
0.035) were significant independent predictors of MBF. Finally, only in the obese group
leptin plasma levels significantly correlated with MBF (r  0.37, p  0.036).
CONCLUSIONS Increased body weight is independently associated with abnormal coronary circulatory
function that progresses from an impairment in endothelium-related coronary vasomotion in
overweight individuals to an impairment of the total vasodilator capacity in obese individuals.
The findings that elevated leptin plasma levels in patients that are obese might exert beneficial
effects on the coronary endothelium to counterbalance the adverse effects of increases in body
weight on coronary circulatory function should be tested. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.0621188–95) © 2006 by the American College of Cardiology Foundation
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ohe prevalence of obesity in the U.S. has increased between
994 and 2000 from 22.9% to 30.5%. Because obesity is
ecognized as a risk factor of cardiovascular morbidity and
ortality, the increasing incidence of obesity is of consid-
rable public health concern (1). The mechanisms by which
besity initiates and accelerates vascular disease are still
oorly understood. The functional integrity of the vascular
ndothelium exerts antiatherosclerotic and antithrombotic
ffects (2). Conversely, impaired endothelium-dependent
oronary vasomotor function describes a proatherosclerotic
tate with substantial diagnostic and prognostic implications
3,4). Previous studies have reported an association between
besity and endothelial dysfunction of the peripheral circu-
ation (5,6). A similar association between obesity and
oronary endothelial dysfunction also has been observed in
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Manuscript received August 6, 2005; revised manuscript received September 30,
005, accepted October 10, 2005.atients with angiographically normal or mildly diseased
oronary arteries and with traditional coronary risk factors
7). Thus, it is tempting to speculate that dysfunctional
ndothelium of the coronary circulation may reflect a mecha-
istic link that confers an increased risk of adverse cardiovas-
ular outcome in obesity. Metabolic abnormalities within the
nsulin resistance syndrome (insulin resistance, hyperinsu-
inemia, hypertension, hypertriglyceridemia, and decreased
igh-density lipoprotein [HDL] cholesterol) and chronic
nflammation commonly parallel the excess of body weight
nd may directly affect the development and progression of
oronary artery disease (CAD) (8,9). To date, the effect of
ncreased body weight, insulin resistance, and of chronic
nflammation on the coronary circulatory function has not
een investigated.
Adipocytokines such as leptin have been implicated as
irect participants in the regulation of coronary vasomotor
unction in obesity (10). For example, the administration of
eptin may stimulate increases in oxidative stress in in vitro
ultured human endothelial cells (11). Increases in oxidative
tress in the vascular endothelium may interact with nitric
xide to form peroxynitrite and, thereby, decrease the
ioavailability of nitric oxide, which is associated with an
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his theory is in contrast to findings in leptin-deficient mice,
n whom the administration of leptin restored endothelium-
ependent vasodilation by receptor-mediated endothelial re-
ease of nitric oxide (12). These findings suggest a direct
elationship between leptin and the coronary vasomotor tone
hat, however, has not been examined in humans.
The aims of the current study were therefore to evaluate
n normal, overweight, and obese individuals without tradi-
ional coronary risk factors: 1) possible effects of increased
ody weight, insulin resistance, and chronic inflammation
n the coronary circulatory function, and 2) a possible
elationship between leptin plasma levels and coronary
irculatory function.
ETHODS
tudy population and design. A total of 72 persons (35
en and 37 women; mean age 37  11 years) without
raditional coronary risk factors for CAD was studied
rospectively. All participants underwent an initial screen-
ng visit that included a physical examination, electrocar-
iogram (ECG), blood pressure measurements, and routine
lood chemistry. Study participants were only included if
raditional coronary risk factors such as hypercholesterol-
mia (total serum cholesterol 240 mg/dl and/or low-
ensity lipoprotein [LDL] cholesterol155 mg/dl), arterial
ypertension (blood pressure 140/90 mm Hg), smoking,
nd diabetes mellitus (fasting plasma glucose obtained on
ore than two occasions 126 mg/dl) were excluded.
urthermore, study applicants were recruited if they were
ithout a history of variant angina, a family history of
remature CAD, or clinically manifest cardiovascular or any
ther disease. All were normal on physical examination and
ad normal resting ECGs. No study participant was on any
ardiac or vasoactive medication, such as angiotensin-
onverting enzyme inhibitors, calcium-channel blockers, beta-
lockers, or statins. Finally, enrolled study participants were
hen grouped by the body mass index (BMI, kg/m2): control
Abbreviations and Acronyms
ANOVA  analysis of variance
BMI  body mass index
CAD  coronary artery disease
CPT  cold pressor test
CRP  C-reactive protein
CVR  coronary vascular resistance
ECG  electrocardiogram
HDL  high-density lipoprotein
HOMA  Homeostasis Model Assessment
LDL  low-density lipoprotein
MBF  myocardial blood flow
PET  positron emission tomography
ROS  reactive oxygen species
RPP  rate-pressure product
WHR  waist-hip ratioroup, 20  BMI 25 (n  19); overweight group, 25  iMI 30 (n  21); and obese group, BMI 30 (n  32)
7). In addition, the waist-hip ratio (WHR) was measured
nd defined as the minimal abdominal circumference be-
ween the xiphoid process and the iliac crest (waist) divided
y the circumference determined over the femoral heads
hip).
Laboratory tests included plasma glucose, hemoglobin
1c, insulin, free fatty acids, total cholesterol, HDL and
DL cholesterol, triglycerides levels, and high sensitive
-reactive protein (CRP). Assessment of insulin resistance
sing the Homeostasis Model Assessment (HOMA) was
etermined as described previously (13). In each patient,
eptin plasma levels (Radioimmunoassay, Quest Diagnostic,
os Angeles, California) were determined from peripheral
rm vein blood samples. All study participants had a low
robability of significant obstructive CAD, as evidenced by
normal homogenous 13N-ammonia tracer uptake on visual
nspection and polar map analysis of the 13N-ammonia
ositron emission tomography (PET) images at rest and
uring dipyridamole stimulated hyperemia (14). Study par-
icipants refrained from consuming caffeine-containing food
r beverages for 24 h before the PET baseline examina-
ion to determine coronary circulatory function. The study
as approved by the UCLA Institutional Review Board,
nd each study participant signed the approved informed
onsent form.
oninvasive quantification of myocardial blood flow
MBF) with PET. Myocardial blood flow was determined
oninvasively with intravenous 13N-ammonia, serial image
cquisition by PET (ECAT EXACT HR, Siemens/CTI
odel 931/08-12, Siemens AG, Munich, Germany), and a
wo-compartment tracer kinetic model (15). The relative
yocardial perfusion was assessed by visual inspection and
olar map analysis of the 13N-ammonia PET images.
ime-activity curves derived from the first 12 dynamic
rames were used to determine absolute estimates of mean
BF in ml/g/min (15). Measurements of MBF using PET
ere performed at baseline, during cold pressor test (CPT;
eflecting predominantly endothelium-dependent vasomo-
ion), and during dipyridamole-induced hyperemia with
tandard dose dipyridamole (140 g/kg/min; reflecting
redominantly endothelium-independent vasomotion) as
escribed previously (16,17). The change in the MBF from
est to CPT was defined as MBF.
Heart rate, blood pressure, and a 12-lead ECG were
ecorded continuously during each MBF measurement.
rom the average of heart rate and blood pressure during
he first 2 min of each image acquisition, the rate-pressure
roduct (RPP) was determined as an index of cardiac work.
n index of coronary vascular resistance (CVR) was deter-
ined as the ratio of mean arterial blood pressure to MBF
mm Hg/ml/min/g).
tatistical analysis. Data are presented as mean  SD for
uantitative and absolute frequencies for qualitative vari-
bles. For comparison of differences, appropriate t tests for
ndependent or paired samples were used (Statistical Anal-
y
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Body Weight and Microvascular Dysfunction March 21, 2006:1188–95sis Software Institute, Cary, North Carolina). A comparison
f CPT-induced change in MBF and dipyridamole MBFs
etween the different groups was performed by two-way
nalysis of variance (ANOVA), followed by Scheffe’s multiple
omparison test. Pearson’s correlation coefficient (r), assuming
linear regression, was calculated to investigate the associations
etween CPT- and dipyridamole-induced changes in MBFs
nd laboratory parameters.Multivariate analysis was performed
ith the linear regression model. Statistical significance was
ssumed if the null hypothesis could be rejected at p 0.05.
ESULTS
atient characteristics and metabolic profile. The clinical
haracteristics of the three study groups are given in Table 1.
he increase in BMI in the three study groups was
aralleled by the WHR so that BMI and WHR signifi-
antly correlated (r  0.60, p  0.0001). Overweight and
bese groups demonstrated significantly lower levels of HDL
holesterol compared with the control group, whereas total and
DL cholesterol levels were similar among groups. Fasting
lasma glucose, triglycerides, and leptin plasma levels were
ignificantly higher in the obese than in the control group but
id not differ significantly between the control and over-
eight groups. Furthermore, insulin, the HOMA as index
or insulin resistance, and high-sensitive CRP were signif-
cantly elevated in the overweight and obese groups com-
ared with the control group. Although the differences in
lasma insulin and HOMA index were significant between
he overweight and obese groups, statistically there was no
ifference in high-sensitive CRP levels. Finally, no differ-
nce among all three groups with regard to free fatty acids
nd HbA1c levels was found.
orrelations between metabolic parameters. In the entire
tudy population, Pearson’s regression analysis revealed
ignificant correlations between BMI and insulin resistance
Table 1. Characteristics of Study Population (
Contro
(n  1
BMI, kg/m2 23  1
Waist-hip ratio 0.81  0
Age, yrs 37  1
Gender, F/M 11/8
Lipid status
Serum cholesterol levels, mg/dl 180  2
Serum LDL level, mg/dl 113  2
Serum HDL level, mg/dl 48  9
Triglyceride level, mg/dl 97  6
Glucose level, mg/dl 82  1
Insulin, mcU/ml 5.1  2
HOMA 1.02  0
Free fatty acids, mmol/l 0.57  0
CRP levels, mg/l 0.77  0
HbAlc, % 5.3  0
Leptin, ng/ml 9.82  6
Values are mean  SD. *p  0.05 vs. control.
BMI  body mass index; CRP  C-reactive protein; HbA
HOMA  Homeostasis Model Assessment; LDL  low-densHOMA) (r  0.60, p  0.0001), BMI and leptin (r  0.52,
 0.0001), and leptin and insulin resistance (HOMA) (r 
.40, p  0.0009), indicating an interrelation between these
etabolic parameters. High-density lipoprotein cholesterol
lso showed significant and inverse correlations with BMI (r
0.34, p  0.004) and with insulin resistance (HOMA,
 0.33, p  0.006) but none with leptin (r  0.02, p 
S). Furthermore, the regression analysis demonstrated
lso significant correlations between BMI and high-
ensitive CRP plasma levels (r  0.47, p  0.0001), insulin
esistance (HOMA) and high-sensitive CRP (r 0.34, p
.009), HDL and high-sensitive CRP (r  0.26, p 
.04), and leptin and high-sensitive CRP (r  0.40, p 
.0001), relating metabolic and inflammatory cardiovascular
isease mechanism together.
emodynamic parameters. At baseline, heart rate and
lood pressures were comparable among the study groups
Table 2). Sympathetic stimulation with CPT lead to
ignificant increases in heart rate and systolic and diastolic
lood pressure (p  0.05), that did not differ between the
hree groups. Consequently, RPPs were similar between the
hree groups either at baseline or during CPT (Table 2).
urthermore, the percent change of RPP to CPT in the
ontrol, overweight, and obese group was similar
%RPP: 39  20% vs. 37  20% vs. 39  23%,
espectively). Pharmacologic vasodilation with dipyrid-
mole produced significant increases in heart rate in the
hree study groups (p  0.05), whereas systolic and
iastolic blood pressures remained essentially unchanged
rom baseline. No significant differences in heart rate or
PP existed between the three study groups during
harmacologic vasodilation.
yocardial blood flow. At baseline, MBF did not differ
mong the three groups (Table 2, Fig. 1). Cold pressor
est-induced MBFs were significantly less in the obese
72)
Overweight
(n  21)
Obesity
(n  32)
27  1.2* 34  3.8*
0.92  0.12* 1.04  0.10*
38  10 37  10
10/11 16/16
190  47 188  28
121  46 113  25
43  7* 41  8*
138  75 177  85*
87  11 93  13*
9.0  4.3* 15.1  10.0*
1.90  0.96* 3.3  1.96*
0.70  0.35 0.65  0.24
2.54  2.61* 3.81  2.80*
5.4  0.35 5.6  0.29
12.85  8.82 20.44  11.14*n 
ls
9)
.4
.11
3
8
4
5
4
.3
.50
.27
.81
.43
.44lc  hemoglobin Alc; HDL  high-density lipoprotein;
ity lipoprotein.
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March 21, 2006:1188–95 Body Weight and Microvascular Dysfunctionroup than in the control group (Table 2, Fig. 1). Further-
ore, MBFs during CPT in the obese group were signifi-
antly lower than in the overweight group (Table 2, Fig. 1).
lthough the MBF during CPT in the overweight group
as lower than in the control group, statistically it did not
each significance (Table 2, Fig. 1). When looking at the
Table 2. Hemodynamic Results and Myocardi
Positron Emission Tomography
Contro
Hemodynamics at rest
Heart rate (beats/min) 65  1
Blood pressure (mm Hg)
Systolic 114  1
Diastolic 69  8
RPP 7,366  1
CPT
Heart rate (beats/min) 75  1
Blood pressure (mm Hg)
Systolic 137  2
Diastolic 82  1
RPP 10,194  1
Pharmacologic vasodilation
Heart rate (beats/min) 98  1
Blood pressure (mm Hg)
Systolic 113  1
Diastolic 68  1
RPP 11,015  1
MBF (ml/min/g myocardium)
At rest 0.61  0
During CPT 0.93  0
 change to CPT 0.32  0
Pharmacologic vasodilation 2.04  0
CVR (mm Hg/ml/min/g)
At rest 141  3
During CPT 110  2
 change to CPT 31  2
Pharmacologic vasodilation 42  1
Values are mean  SD. *p  0.05 vs. control group.
CPT cold pressor test; CVR coronary vascular resista
igure 1. Myocardial blood flow (MBF) at rest, during cold pressor testing
CPT), and during pharmacologic vasodilation with dipyridamole for the
hree study groups (significant difference by t test).
F
tMBF to CPT, it was significantly less in the overweight
nd obese groups than in the control group, respectively
Table 2, Fig. 2). Furthermore, MBF was significantly
ore reduced in the obese group than in the overweight
roup (Table 2, Fig. 2). The group comparison between the
MBF in the control group was significant as compared
ith the overweight and obese groups (p  0.0001 by
NOVA). Dipyridamole MBFs and, thus, the total vaso-
od Flow (MBF) During
Group
Overweight Obesity
64  6 67  8
109  12 111  11
66  8 67  9
7,023  937 7,494  1,071
70  7 75  10
137  18 137  18
82  8 84  13
9,548  1,221 10,314  1,703
91  9 96  13
114  15 117  14
64  7 71  11
10,354  1,771 11,487  1,934
0.64  0.15 0.63  0.17
0.84  0.21 0.70  0.20*
0.21  0.19* 0.07  0.16*
1.94  0.52 1.77  0.51*
135  43 142  45
126  33 159  49*
9  42* 17  40*
43  12 52  16*
BFmyocardial blood flow; RPP rate-pressure product.al Blo
l
0
7
,380
1
2
1
,380
7
5
0
,966
.12
.17
.09
.37
0
1
3
1igure 2. Change of myocardial blood flow (MBF) during cold pressor
esting (CPT) for the three study groups (significant difference by t test).
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Body Weight and Microvascular Dysfunction March 21, 2006:1188–95ilator capacity, were statistically not significantly lower in
he overweight group compared with the control group but
ere significantly less in the obese group (Table 2, Fig. 1).
ipyridamole MBFs did not differ significantly between the
verweight and obese group (Table 2, Fig. 1). The group
omparison of dipyridamole MBFs was not significant (p 
S by ANOVA). To account for interindividual variations
n the coronary driving pressure, an index of CVR was
alculated as ratio of mean arterial blood pressure to MBF.
s depicted in Table 2, the CVR at rest, during CPT, and
harmacologic vasodilation reflected those of MBF for each
tudy group.
hanges in MBF related to leptin plasma levels. Pearson
egression analysis did not show a significant correlation
etween leptin plasma levels and MBF to CPT in the
ntire study population (Fig. 3). Also, leptin plasma levels
id not correlate with dipyridamole MBFs (r  0.07, p 
S). In the overweight group, the regression analysis
etween leptin plasma levels and MBF did not correlate
Fig. 4), whereas in the obese group a significant association
igure 3. Correlation between leptin plasma levels and change of myocar-
ial blood flow (MBF) during cold pressor testing (CPT) in the entire
tudy group.
igure 4. Correlation between leptin plasma levels and change of myocar-
ial blood flow (MBF) during cold pressor testing (CPT) in the
verweight group.
H
Las found (Fig. 5). Thus, in the obese group higher leptin
lasma levels were associated with relatively higher MBFs.
n regard to leptin plasma levels and dipyridamole MBFs,
he regression analysis did not show an association for either
he overweight group (r 0.10, pNS) or the obese group
r  0.15, p  NS).
eterminants of MBF. In the entire study group, on
nivariate analysis only BMI, HDL cholesterol, HOMA,
nd CRP levels were significantly associated with MBF
Table 3). As demonstrated in Table 3, by multivariate
nalysis only BMI and age remained statistically indepen-
ently predictors of MBF. The univariate analysis in the
verweight group (Table 4) demonstrated age to be signif-
cantly associated with MBF. By multivariate analysis
one of the parameters was an independent predictor of the
MBF (p  NS). Finally, on univariate analysis in the
bese group (Table 5), only leptin plasma levels were
ignificantly associated with MBF. By multivariate analy-
is leptin plasma levels and HDL were independently
igure 5. Correlation between leptin plasma levels and change of myocar-
ial blood flow (MBF) during cold pressor testing (CPT) in the obese
roup.
able 3. Entire Study Group
MBF to CPT
Univariate
Multivariate Analysis
p Value
Standardized
Coefficient p Value
eptin, ng/ml 0.44 0.45 0.06
MI, kg/m2 0.0001* 1.75 0.012*
otal cholesterol, mg/dl 0.79 1.80 0.64
DL cholesterol, mg/dl 0.58 0.98 0.68
DL cholesterol, mg/dl 0.009* 0.09 0.93
riglyceride, mg/dl 0.07 0.37 0.60
lucose, mg/dl 0.11 1.08 0.89
OMA 0.02* 0.23 0.26
RP, mg/l 0.048* 0.04 0.80
ge, yrs 0.08 0.75 0.035*
ender 0.47 0.16 0.31
Significant difference by analysis of variance.
BMI  body mass index; CPT  cold pressor test; CRP  C-reactive protein;
DL  high-density lipoprotein; HOMA  Homeostasis Model Assessment;
DL  low-density lipoprotein; MBF  myocardial blood flow.
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March 21, 2006:1188–95 Body Weight and Microvascular Dysfunctionssociated with the MBF. Further, regarding the attenu-
ted dipyridamole MBFs in the obese group, on univariate
nalysis only age showed a significant association with the
BFs during dipyridamole (p  0.029), whereas on mul-
ivariate analysis none of the parameters were independently
redictive for the dipyridamole MBFs.
ISCUSSION
he results of the present study provide several new find-
ngs. First, increased body weight, paralleled by an increase
n plasma markers of the insulin-resistance syndrome and
hronic inflammation, is independently associated with
bnormal coronary circulatory function that progresses from
n impairment in endothelium-dependent coronary vaso-
otion in overweight individuals to an impairment of the
otal vasodilator capacity in obese individuals. This progres-
ive worsening of the coronary circulatory function might
rovide a mechanistic link between abnormal coronary
asomotion and adverse cardiovascular outcome. Second, in
he obese individuals, increased leptin plasma levels were
ignificantly associated with relatively higher endothelium-
ediated MBF increases to CPT, which might reflect a
eneficial effect of leptin and/or leptin-related but still-
ndetermined factors on the coronary vascular endothelium
o counteract the adverse effects of increases in body weight
n coronary vasomotor function.
MI and coronary vascular function. Steinberg et al. (5),
n their observations, were first to demonstrate that obesity
s associated with peripheral endothelial dysfunction, which
ay be related to insulin resistance. Recent findings support
he Steinberg et al. (5) observations by adding (16) that
ndothelium-mediated coronary vasodilation is progres-
ively impaired with increasing severity of insulin resistance
nd carbohydrate intolerance. Al Suwaidi et al. (7) studied
he coronary vascular reactivity in a large group of 397
onsecutive patients with angiographically normal or mildly
iseased coronary arteries. These patients were mostly
able 4. Overweight Group
MBF to CPT
Univariate
Multivariate Analysis
p Value
Standardized
Coefficient p Value
eptin, ng/ml 0.80 0.45 0.06
MI, kg/m2 0.36 0.25 0.93
otal cholesterol, mg/dl 0.67 1.44 0.81
DL cholesterol, mg/dl 0.64 0.90 0.82
DL cholesterol, mg/dl 0.16 0.77 0.73
riglyceride, mg/dl 0.46 0.25 0.86
lucose, mg/dl 0.76 1.67 0.56
OMA 0.36 0.14 0.83
RP, mg/l 0.56 0.51 0.40
ge, yrs 0.002* 2.45 0.08
ender 0.21 0.19 0.61
Significant difference by analysis of variance.
Abbreviations as in Table 3.reated for coronary risk factors such as hypertension,
*ypercholesterolemia, and diabetes; 48% of them were also
mokers. Notably, Al Suwaidi et al. (7) identified obesity as
n independent predictor of coronary endothelial dysfunc-
ion, strongly suggesting obesity as a possible alternate
ediator of coronary vascular disease rather than as an
piphenomenon related to other traditional coronary risk
actors commonly associated with obesity. This observation
ppears to be consistent with recent ones in obese individ-
als and components of the metabolic syndrome (18), where
he waist circumference (as an anthropomorphic index for
ody weight) and systolic blood pressure were indepen-
ently related to peripheral endothelial dysfunction.
However, adding HOMA index of insulin resistance
emoved the independent contribution of waist circumfer-
nce in the modulation of endothelial dysfunction. There-
ore, it is equally possible that the effects of obesity on
ndothelial dysfunction are primarily related to insulin
esistance. In particular, this premise may hold true because
besity is a major cause of insulin resistance and chronic
nflammation (8,9). Because previous assessment of coro-
ary vasoreactivity (7) did not evaluate the effect of insulin
esistance and chronic inflammation on coronary endothe-
ial function, it remains uncertain whether obesity does
ndeed independently contribute to the determination of
oronary endothelial dysfunction. The results of the current
tudy in a relatively young study population provide first
vidence that, indeed, increases in body weight exert a direct
ffect on coronary endothelial dysfunction independent of
verweight- and obesity-related insulin resistance and
hronic inflammation. Interestingly and also contrary to a
revious investigation (7), impaired coronary vasodilator
unction was not confined to endothelium-mediated mech-
nism but extended to an impairment in predominantly
ndothelium-independent MBF increases to pharmacologic
asodilation in obesity. We also found that endothelium-
ediated MBF increases to CPT were not only impaired in
besity but also in overweight individuals. This observation
ay indicate that, even in otherwise-healthy individuals,
able 5. Obese Group
MBF to CPT
Univariate
Multivariate Analysis
p Value
Standardized
Coefficient p Value
eptin, ng/ml 0.036* 0.45 0.033*
MI, kg/m2 0.91 1.99 0.20
otal cholesterol, mg/dl 0.73 23.3 0.07
DL cholesterol, mg/dl 0.80 12.99 0.09
DL cholesterol, mg/dl 0.94 6.78 0.047*
riglyceride, mg/dl 0.76 4.10 0.10
lucose, mg/dl 0.20 1.29 0.42
OMA 0.76 0.03 0.94
RP, mg/l 0.55 0.07 0.85
ge, yrs 0.56 0.01 0.99
ender 0.24 0.42 0.29Significant difference by analysis of variance.
Abbreviations as in Table 3.
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reased risk for future cardiovascular events (3,4).
In the current study population, components of the
etabolic syndrome such as BMI, HDL cholesterol, insulin
esistance, and CRP plasma level were predictive of the
lterations in MBF to sympathetic stimulation. By multi-
ariate analysis, however, only BMI and age remained
ndependent predictors of the CPT-induced changes in
BF. Because on regression analysis BMI revealed signif-
cant associations with components of the metabolic syn-
rome (low HDL cholesterol, insulin resistance, and CRP
lasma levels), the independent predictive value of BMI for
PT-induced MBF alterations also suggests that a complex
nterplay of low HDL cholesterol, insulin resistance, and
ystemic inflammation affects endothelium-dependent cor-
nary vasomotor function with increases in body weight
8,19). Thus, these results add further evidence for increased
ody weight as an important integrating determinant of
oronary vascular homeostasis (8). Interestingly, the age of
tudy participants also proved to independently predict
hanges in MBF to cold exposure, which may indicate the
ndothelium-related change in MBF is not only be related
o the age of the study participants and the numbers of
ardiovascular risk factors (2) but also to the duration of its
xposure (20,21).
The reason for the mechanistic link between increases in
ody weight and the progressive impairment of coronary
irculatory function is not fully understood but is likely multi-
actorial in etiology, possibly being related to alterations in
lucose tolerance, lipid profile, triglycerides, and microinflam-
ation (9). Apart from insulin resistance, elevated plasma free
atty acid levels combined with increased plasma triglycerides
nd small, dense LDL bodies may alter intracellular signaling
f the nitric oxide synthase activity (2,9). In addition, increases
n reactive oxygen species (ROS) through activation of
icotinamide-adenine-dinucleotide phosphate oxidase may di-
inish the bioavailability of endothelium-derived nitric oxide
22,23). Beneficial effects of acute antioxidant vitamin C
hallenges on endothelial dysfunction of the brachial artery
24) indeed suggests the involvement of ROS underlying
ndothelial dysfunction in obesity. The contribution of
OS in mediating abnormal coronary vasomotion in obe-
ity, however, remains to be determined.
dipocytokine leptin and coronary vasomotion. Leptin
s primarily synthesized in adipocytes and its concentration
as been shown to increase as a direct function of increasing
ercentage body fat, even though for the same amount of
ody fat there can be up to threefold differences in leptin
evels (10,25). Notably, leptin specifically targets receptors
n the vascular endothelium and smooth muscle cells (10)
hat in in vitro studies have been shown to lead to leptin-
timulated prothatherosclerotic effects, such as increases in
OS in cultured human endothelial cells (11), acceleration
f vascular cell calcification, smooth muscle cell prolifera-
ion, and migration (10). Furthermore, in a mice model
levated leptin plasma levels appear to directly mediaterterial thrombotic disease in vivo (26). On the other hand,
eptin has been demonstrated to evoke both endothelium-
ependent and -independent vasorelaxation (27,28). Intra-
oronary infusion of leptin in humans with angiographically
ormal coronary arteries also may directly lead to a coronary
asodilation of the conduit and arteriolar vessels (29).
In addition, there is, in conclusion, a large body of in vivo
vidence indicating that leptin may stimulate increases in
he release of endothelium-derived nitric oxide in a rat
odel (12,28,30), suggesting important antiatherosclerotic
nd antithrombotic effects (2). In the current study, we
ound a significant association (r  0.37, p  0.036)
etween increases in leptin plasma levels and CPT-induced
hanges in MBF in the obese, whereas there was no such
ssociation in overweight and in the study populations as a
hole. Thus, in obese individuals, increased leptin plasma
evels were associated with relatively higher increases in
BF to CPT, which could possibly reflect a beneficial effect
f leptin and/or leptin-related but still undetermined factors
n the coronary endothelium. The latter observation is also
onsistent with the observed beneficial effects of leptin
dministration on endothelium-dependent vasomotion in
bese leptin knockout mice (12). However, to provide more
efinite answers regarding the role of leptin in the regula-
ion of coronary vasomotor control in obesity further studies
re needed.
onclusions. This study demonstrates for the first time
hat increased body weight, paralleled by an increase in
lasma markers of the insulin-resistance syndrome and
hronic inflammation, is independently associated with
bnormal coronary circulatory function that progresses from
n impairment in endothelium-related coronary vasomotion
n overweight individuals to an impairment of the total
asodilator capacity in obese individuals. Moreover, the
nding that elevated plasma leptin levels in obesity might
xert beneficial effects on the coronary endothelium to
ounterbalance the adverse effects of increases in body
eight on coronary circulatory function warrants further
nvestigations.
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